HOUSTON -- Two-thirds of patients with PI3K-mutant brain metastases responded to the maximum tolerated dose (MTD) of the small-molecule inhibitor paxalisib plus radiation therapy (RT), a small phase I ...
Second clinical candidate from HUTCHMED’s next-generation ATTC platform —— Leveraging synergy through simultaneous inhibition of PAM pathway ...
OnKure Therapeutics, Inc. (OKUR) is gearing up for a major event in Q4 of 2024, which is that it intends to release data from its phase 1 PIKture-01 study using OKI-219 for the treatment of solid ...
BLU-222, an investigational, oral, potent, and highly selective CDK2 inhibitor (CDK2i), as monotherapy in patients (pts) with advanced solid tumors and in combination with ribociclib (RIBO) and ...
Combining multiple kinase inhibitors may present off-target risks or unbalanced inhibition among different targets, that may be solved using rationally designed small molecules. Researchers from ...
Forschungsverbund Berlin eV has divulged phosphatidylinositol 4-phosphate 3-kinase (PI3K) inhibitors, particularly PI3K C2 domain-containing subunit β (PIK3C2B) inhibitors, reported to be useful for ...
Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. There are several clinical trials that are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results